Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Decitabine in Relapsed or Refractory MDS/AML
NCT02890329Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ipilimumab in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (6 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose (Recommended Phase 2 Dose) of Ipilimumab in Combination With Decitabine at 8 weeks. Started Sep 2017; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02890329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890329.